Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genfar

- PMLiVE

BRIC ‘not delivering’ on promises of high growth

Frost & Sullivan report highlights the difficulties for pharma working in BRIC markets

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

Building BRICs: pharma’s key emerging markets are becoming giants

The BRIC nations – Brazil, Russia, India and China – for so long the leading lights of the emerging markets movement, may soon need to relinquish their 'emerging' tag and...

- PMLiVE

Pay-for-delay deals lead to inflated drug prices says study

Based on analysis of delayed market entry of generic Adderall XR in US

Teva and Sun pay dearly for ‘at-risk’ generic Protonix launch

Will pay $2.15bn in landmark patent infringement lawsuit

- PMLiVE

FDA approves Sanofi’s four-in-one flu vaccine

But wants more safety data for hepatitis B vaccine from Dynavax

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

Sanofi reception

Sanofi reconsiders closure plans in Toulouse after government pressure

Report says research site can remain open with minimal job losses

Sanofi reception

Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis

- PMLiVE

Sanofi partners with PatientsLikeMe to promote its clinical trials

Online patient community will match patients to the pharma company's trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links